Ceregene
San Diego, California, United States
About Ceregene
Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $71.5M
- Funding stage: M&A
- Last round: Series D (Nov 2010)
- Website: ceregene.com
- Phone: (858)458-8800
Industries & Categories
Biotechnology, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ceregene-2548578 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.